The incidence of vitiligo and its clinical features in response to Psoralen group of drugs and associated other diseases

---

Original Article

Author Details : Girish V. Nagaral, Karibasappa

Volume : 2, Issue : 3, Year : 2016

Article Page : 102-105

Suggest article by email

Get Permission

---

Abstract

Background: Vitiligo incidence and treatment modalities are diverse and remain unsatisfactory. There is high incidence of vitiligo among patients suffering from systemic disorders.
Aim: The present study was undertaken to study the incidence of vitiligo and its response to psoralen group of drugs and association with other diseases.
Methodology: 150 patients attending the outpatient department of Dermatology, Venereology and leprology at Chitageri General Hospital and Bapuji Hospital attached to J.J.M Medical College, Davengere were utilized for the current to study clinical features in response to psoralen group drugs in vitiligo and its association with other diseases.
Results: The incidence of vitiligo was at around 1.49% in the present study. The localized type was 46.7% and spread type 14% and vulgaris type 2.7% was observed in the current study. Among 50 cases which were studied with psoralen groups of drugs; vitiligo repigmentation occurred in 11 patients treated with 8-Methoxy Psoralen (8MOP) and 1 patient treated with Tri-methyl Psoralen (TMP) and 2 patients treated with Psoralen alone in the present study was recorded. 5 patients out of 130 were associated with other diseases of 2 with Diabetes mellitus, 1 each of Psoriasis, alopecia areata and borderline tuberculoid leprosy observed in the present study.
Conclusion: Awareness should be given to the vitiligo patients on its incidence, type and role of psoralen drugs in treatment. Psoralen group drugs could give better results in treatment of vitiligo than other drugs.

Keywords: Incidence, Psoralen drugs, Vitiligo

 

How to cite : Nagaral G V, Karibasappa, The incidence of vitiligo and its clinical features in response to Psoralen group of drugs and associated other diseases. IP Indian J Clin Exp Dermatol 2016;2(3):102-105

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.